{"title":"Cerebral Toxoplasmosis in a Patient with Chronic Lymphocytic Leukemia Treated With Obinutuzumab- Chlorambucil","authors":"Vellemans Hélène","doi":"10.34297/ajbsr.2021.14.001968","DOIUrl":null,"url":null,"abstract":"Despite therapeutic advances, infectious complications continue to play a significant role in the clinical course of patients with CLL. Cerebral toxoplasmosis is among the most common CNS infections in immunocompromised patients. Toxoplasma gondii can cause a life threatening CNS or disseminated infection, usually due to reactivation of a latent infection. We describe here the case of a 76 year-old man who developed toxoplasmic encephalitis after a treatment with obinutuzumab-chlorambucil for a CLL. He was admitted to the emergency room for confusion, agitation, Brocca aphasia, diplopia and left mydriasis seven months after the end of treatment with obinutuzumab-chlorambucil. Brain MRI showed at least eight intra-axial supra-tentorial lesions. A brain biopsy was performed and showed a florid toxoplasmosis. Rapidly, treatment with TMP-SMX was started and an improvement in the patient neurological condition was gradually observed. This is the first case of cerebral toxoplasmosis described after treatment with obinutuzumab-chlorambucil in a patient with CLL.","PeriodicalId":93072,"journal":{"name":"American journal of biomedical science & research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of biomedical science & research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34297/ajbsr.2021.14.001968","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Despite therapeutic advances, infectious complications continue to play a significant role in the clinical course of patients with CLL. Cerebral toxoplasmosis is among the most common CNS infections in immunocompromised patients. Toxoplasma gondii can cause a life threatening CNS or disseminated infection, usually due to reactivation of a latent infection. We describe here the case of a 76 year-old man who developed toxoplasmic encephalitis after a treatment with obinutuzumab-chlorambucil for a CLL. He was admitted to the emergency room for confusion, agitation, Brocca aphasia, diplopia and left mydriasis seven months after the end of treatment with obinutuzumab-chlorambucil. Brain MRI showed at least eight intra-axial supra-tentorial lesions. A brain biopsy was performed and showed a florid toxoplasmosis. Rapidly, treatment with TMP-SMX was started and an improvement in the patient neurological condition was gradually observed. This is the first case of cerebral toxoplasmosis described after treatment with obinutuzumab-chlorambucil in a patient with CLL.